Novel glucocorticoid receptor agonists in the treatment of asthma

Bibliography

• Thomson NC, Chaudhuri R, Spears M. Emerging therapies for severe asthma. BMC Med 2011;9:102
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469–78
   PubMed Web of Science ®Google Scholar
• Anonymous. PharmaPoint: asthma global drug forecast and market analysis to 2023. Available from: http://www.researchandmarkets.com/reports/3044361/pharmapoint-asthma-global-drug-forecast-and [Last accessed 17 June 2015]
   Google Scholar
• Quirce S, Bobolea I, Barranco P. Emerging drugs for asthma. Expert Opin Emerg Drugs 2012;17(2):219–37
   PubMed Web of Science ®Google Scholar
• Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014;349:g5517
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. Available from: http://www.ginasthma.org/
   Google Scholar
• Barnes P. New therapies for asthma. Trends Mol Med 2006;12(11):515–20
   PubMed Web of Science ®Google Scholar
• Hillier SG. Diamonds are forever: the cortisone legacy. J Endocrinol 2007;195(1):1–6
   PubMed Web of Science ®Google Scholar
• Colice G. Emerging therapeutic options for asthma. Am J Manag Care 2011;17(Suppl 3):S82–9
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticoids. Chem Immunol Allergy 2014;100:311–16
   PubMedGoogle Scholar
• Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids. Curr Opin Allergy Clin Immunol 2011;11(4):337–44
   PubMed Web of Science ®Google Scholar
• Marandi Y, Farahi N, Hashjin GS. Asthma: beyond corticosteroid treathment. Arch Med Sci 2013;9(3):521–6
   Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163(1):29–43
   PubMed Web of Science ®Google Scholar
• Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol Annu Rev 2006;12:269–300
   PubMedGoogle Scholar
• Takahashi H, Razavi H, Thomson D. Recent progress in the discovery of novel glucocorticoid receptor modulators. Curr Top Med Chem 2008;8(6):521–30
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008;73(9-10):1025–9
   PubMed Web of Science ®Google Scholar
• van der Molen T, Kocks JW. The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? NPJ Prim Care Respir Med 2014;24:14013
   Google Scholar
• Rossi G, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007;20(1):23–35
   PubMed Web of Science ®Google Scholar
• Strehl C, Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks. Mol Cell Endocrinol 2013;380(1-2):32–40
   PubMed Web of Science ®Google Scholar
• Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 2012;134(1):54–67
   PubMed Web of Science ®Google Scholar
• Norman P. Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423). Expert Opin Ther Pat 2013;23(9):1239–45
   PubMed Web of Science ®Google Scholar
• Ayroldi E, Macchiarulo A, Riccardi C. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective. FASEB J 2014;28(12):5055–70
   PubMed Web of Science ®Google Scholar
• Pujols L, Mullol J, Torrego A, Picado C. Glucocorticoid receptors in human airways. Allergy 2004;59(10):1042–52
   PubMed Web of Science ®Google Scholar
• Patel R, Williams-Dautovich J, Cummins CL. Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol Endocrinol 2014;28:999–1011
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120(2-3):76–85
   PubMed Web of Science ®Google Scholar
• Pujols L, Mullol J, Pérez M, et al. Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol 2001;24(1):49–57
   PubMed Web of Science ®Google Scholar
• Chikanza IC. Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann NY Acad Sci 2002;966:39–48
   PubMed Web of Science ®Google Scholar
• Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann NY Acad Sci 2006;1069:1–9
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Haegeman G. Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol 2009;23(3):281–91
   PubMed Web of Science ®Google Scholar
• Lösel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003;4:46–56
   PubMed Web of Science ®Google Scholar
• Schäcke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101(1):227–32
   PubMed Web of Science ®Google Scholar
• Sundahl N, Bridelance J, Libert C, et al. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. Pharmacol Ther 2015;152:28–41
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001;166:1975–82
   PubMed Web of Science ®Google Scholar
• Dezitter X, Fagart J, Taront S, et al. A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation. Mol Pharmacol 2014;85(2):226–36
   PubMed Web of Science ®Google Scholar
• Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003;17(5):860–9
   PubMed Web of Science ®Google Scholar
• Burris TP, Solt LA, Wang Y, et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 2013;65(2):710–78
   PubMed Web of Science ®Google Scholar
• Chen T. Nuclear receptor drug discovery. Curr Opin Chem Biol 2008;12(4):418–26
   PubMed Web of Science ®Google Scholar
• Humphrey EL, Williams JHH, Davie MWJ, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006;38(5):652–61
   PubMed Web of Science ®Google Scholar
• Lopez FJ, Ardecky RJ, Bebo B, et al. LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 2008;149(5):2080–9
   PubMed Web of Science ®Google Scholar
• Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile. Proc Natl Acad Sci USA 2007;104(49):19244–9
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005;102(44):15827–32
   PubMed Web of Science ®Google Scholar
• Robertson S, Allie-Reid F, Vanden Berghe W, et al. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound A. J Biol Chem 2010;285:8061–75
   PubMed Web of Science ®Google Scholar
• Dewint P, Gossye V, De Bosscher K, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol 2008;180:2608–15
   PubMed Web of Science ®Google Scholar
• Reber LL, Daubeuf F, Plantinga M, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol 2012;188(7):3478–87
   PubMed Web of Science ®Google Scholar
• Norman P. Boehringer Ingleheim’s selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333. Expert Opin Ther Pat 2011;21(7):1137–42
   Google Scholar
• Norman P. Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423). Expert Opin Ther Pat 2013;23(9):1239–45
   PubMed Web of Science ®Google Scholar
• Kuzmich D, Kirrane T, Proudfoot J, et al. Identification of dissociated non-steroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett 2007;17(18):5025–31
   PubMed Web of Science ®Google Scholar
• Adis Insight. BI 54903. Available from: http://adisinsight.springer.com/drugs/800034697 [Last accessed 21 June 2015]
   Google Scholar
• Razavi H, Riether D, Harcken C, et al. Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore. Bioorg Med Chem Lett 2014;24(8):1934–40
   PubMed Web of Science ®Google Scholar
• Harcken C, Riether D, Kuzmich D, et al. Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects. J Med Chem 2014;57(4):1583–98
   PubMed Web of Science ®Google Scholar
• Harcken C, Riether D, Liu P, et al. Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate. ACS Med Chem Lett 2014;5(12):1318–23
   PubMed Web of Science ®Google Scholar
• Schäcke H, Zollner TM, Döcke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158(4):1088–103
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Cavet ME, VanderMeid KR, et al. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis 2009;15:2606–16
   PubMed Web of Science ®Google Scholar
• Cavet ME, Volhejn S, Harrington KL, Zhang JZ. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 2013;19:1515–25
   PubMed Web of Science ®Google Scholar
• Baiula M, Bedini A, Baldi J, et al. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy. Drug Des Devel Ther 2014;8:745–57
   PubMed Web of Science ®Google Scholar
• Baiula M, Spampinato S. Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. Inflamm Allergy Drug Targets 2014;13(5):289–98
   PubMedGoogle Scholar
• Uings IJ, Needham D, Matthews J, et al. Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile. Br J Pharmacol 2013;169(6):1389–403
   PubMed Web of Science ®Google Scholar
• Bareille P, Hardes K, Donald AC. Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. J Asthma 2013;50(10):1077–82
   PubMed Web of Science ®Google Scholar
• Leaker BR, O’Connor B, Singh D, Barnes PJ. The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. J Allergy Clin Immunol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• van Lierop MJ, Alkema W, Laskewitz AJ, et al. Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. PLoS ONE 2012;7(11):e48385
   PubMed Web of Science ®Google Scholar
• Bungard CJ, Hartman GD, Manikowski JJ, et al. Discovery of selective glucocorticoid receptor modulator MK-5932. Bioorg Med Chem 2011;19(24):7374–86
   PubMed Web of Science ®Google Scholar
• Brandish PE, Anderson K, Baltus GA, et al. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator. Eur J Pharmacol 2014;724:102–11
   PubMed Web of Science ®Google Scholar
• Stock T, Fleishaker D, Mukherjee A, et al. Evaluation of safety, pharmacokinetics and pharmacodynamics of a selective glucocorticoid receptor modulator (SGRM) in healthy volunteers [ abstract]. ACR Annual Meeting; 2009. p. 420
   Google Scholar
• Stock T, Fleishaker D, Wang X, et al. Phase 2 evaluation of PF-04171327, a dissociated agonist of the glucocorticoid receptor, for the treatment of rheumatoid arthritis in patients with an inadequate response to methotrexate [ abstract]. ACR/ARHP Annual Meeting; 2014. p. 2336
   Google Scholar
• Yuen KCJ, Buttgereit F, McCabe D, et al. Profound suppression of endogenous cortisol secretion with PF-04171327 (a dissociated agonist of glucocorticoid receptor) Compared to Prednisone [ abstract]. Endocrine Society’s 97th Annual Meeting; 2015. p. OR06–3
   Google Scholar
• Strand V, Buttgereit F, McCabe D, et al. A PHASE 2, randomized, double-blind comparison of the efficacy and safety of PF-04171327 (1, 5, 10, 15 mg QD) vs 5 and 10 mg prednisone QD or placebo in subjects with rheumatoid arthritis (RA) over 8 weeks followed by a 4-week taper of study drug [ abstract]. ACR/ARHP Annual Meeting; 2014. p. L6
   Google Scholar
• Edman K, Ahlgren R, Bengtsson M, et al. The discovery of potent annormand selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation. Bioorg Med Chem Lett 2014;24(11):2571–7
   PubMed Web of Science ®Google Scholar
• Mardh CK, Gustavsson M, Smailagic A. Pharmacological characterization of AZD5423, an inhaled non-steroidal agonist of the glucocortiocoid receptor [abstract]. Am J Respir Crit Care Med 2015;191:A5656
   Google Scholar
• McWhae A, Shah S, Karrman-Mardh C, et al. The novel glucocorticoid receptor agonist, AZD5423, shows super-agonism relative to the conventional agonists, dexamethasone and budesonide [abstract]. Am J Respir Crit Care Med 2015;191:A1293
   Google Scholar
• Gauvreau GM, Boulet LP, Leigh R, et al. A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med 2015;191(2):161–7
   PubMed Web of Science ®Google Scholar
• Caratti G, Matthews L, Poolman T, et al. Glucocorticoid receptor function in health and disease. Clin Endocrinol (Oxf) 2015. [Epub ahead of print].
   PubMedGoogle Scholar
• Limbourg FP, Liao JK. Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl) 2003;81(3):168–74
   PubMed Web of Science ®Google Scholar
• Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275(1-2):71–8
   PubMed Web of Science ®Google Scholar
• Joshi T, Johnson M, Newton R, Giembycz M. An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics. Br J Pharmacol 2015;172(5):1360–78
   PubMed Web of Science ®Google Scholar